Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains

AIDS Research and Human Retroviruses

Volumn 12, Issue 6, 1996, Pages 507-517

  Zhu, Qing Yu ^a   Scarborough, Alex ^a   Polsky, Bruce ^a   Chou, Ting Chao ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; ZIDOVUDINE;

ARTICLE; CROSS RESISTANCE; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSCRIPTION;

EID: 0029867822     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.507     Document Type: Article

References (44)

1. Larder BA, Darby G, and Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-1734.
2. Rooke R, Tremblay M, Soudeyns H, DeStephano L, Yan X-J, Fanning M, Montaner JSF, O'Shaughnessy M, Gelman K, Tsoukas CD, Gill J, Ruedy J, Wainbberg MA, and Canadian Zidovudine Multi-Center Study Group: Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 1989;3:411-415.
3. Land S, Treloar T, McPhee D, Birch C, Doherty R, Cooper D, and Gust ID: Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. J Infect Dis 1990; 161:326-329.
4. St. Clair MH, Martin JL, Tudor-Williams E, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, and Larder BA: Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-1559.
5. Fitzgibbon JE, Howell RM, Haberettl CA, Sperber SJ, Gocke DJ, and Dubin DT: Human immunodeficiency virus type 1 pol gene mutation which caused decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 1992;36:153-157.
6. Richman DD, Shih C-K, Lowy I, Rose J, Prodanovich P, Goff S, and Griffin J: HIV-1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991;88:11241-11245.
7. Nunberg JH, Schleif WA, Boots EJ, O'Brien JA, Quintero JC, Hoffman AM, Emini EA, Goldman ME: Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991;65:4887-4892.
8. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Baminger K, Pauletti D, Shih C-K, Myers M, and Griffin J: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-1666.
9. + lymphocytes and plasma during therapy. Antiviral Res 1992;18:303-316.
10. Kellam P, Boucher CAB, and Larder BA: Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992;89:1934-1938.
11. Larder BA, Kellam P, and Kemp SD: Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991;5:134-144.
12. Richman DD, Guatelli JC, Grimes J, Tsiatis A, and Gingeras T: Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of polymerase chain reaction. J Infect Dis 1992;164:1075-1081.
13. Larder BA, Coates KE, and Kemp SD: Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol 1991;65:5232-5236.
14. Gao Q, Gu Z, Parniak MA, Li X, and Wainberg MA: In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-deoxythymidine. J Virol 1992;66:12-19.
15. Muckenthaler M, Gunkel N, Levantis P, Broadhurst K, Goh B, Colvin B, Forster G, Jackson GG, and Oxford JS: Sequence analysis of an HIV-1 isolate which displays unusually high-level AZT resistance in vitro. J Med Virol 1992;36:79-83.
16. Clercq ED: HIV resistance to reverse transcriptase inhibitor. Biochem Pharmacol 1994;47:155-169.
17. Larder BA and Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine. Science 1989;246:1155-1158.
18. Richman DD: Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993;37:1207-1213.
19. Koshida R, Vrang L, Gilljam G, Harmendberg J, Oberg B, and Wahren B: Inhibition of human immunodeficiency virus in vitro by combinations of 3′-azido-3′-deoxythymidine and foscarnet. Antimicrob Agents Chemother 1989;33:778-780.
20. Schinazi RF, Cannon DL, Arnold BH, and Tzman DM: Combinations of isoprinosine and 3′-azido-3′-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother 1988;32:1784-1787.
21. Hyashi S, Fine RL, Chou T-C, Currens MJ, Broder S, and Mitsuya H: In vitro infection of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2′,3′-dedeoxynucleosides and virus-binding inhibitors. Antimicrob Agents Chemother 1990;34:82-88.
22. Craig JC, Whittaker L, Duncan IB, and Roberts NA: In vitro anti-HIV and cytotoxicological evaluation of the triple combination: AZT and ddC with HIV proteinase inhibitor saquinavir (RO31-8959). Antiviral Chem Chemother 1994;5:380-386.
23. Shafer RW, Kozal MJ, Winters MA, Iversen AN, Katzenstein DA, Ragni MV, Meyer WA III, Gupta P, Rasheed S, Coombs R, Katzman M, Fiscus S, and Merigan TC: Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994;169:722-729.
24. Eron JJ Jr, Johnson VA, Merrill DP, Chou T-C, and Hirsch MS: Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro. Antimicrob Agent Chemother 1992;36:1559-1562.
25. Sorensen AM, Nielsen C, Mathiesen LR, Nielsen JO, and Hansen JS: Evaluation of the combination effect of different antiviral compounds against HIV in vitro. Scand J Infect Dis 1993;25:365-371.
26. Chou T-C and Talalay P: Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. In: New Avenues in Development of Cancer Chemotherapy. Bristol-Meyers Symposium Series (Harrap KP and Connors TA, eds.). Academic Press, New York, 1987, pp. 37-64.
27. Chou T-C: Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976;39:253-276.
28. 50, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics. IBM-PC software and manual. Biosoft, Cambridge, 1987.
29. Chou J: Quantitation of synergism and antagonism of two or more drugs by computerized analysis. In: Synergism and Antagonism in Chemotherapy (Chou T-C and Rideout DC, eds.). Academic Press, New York, 1991, pp. 223-244.
30. Chou T-C: The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Synergism and Antagonism in Chemotherapy (Chou T-C and Rídeout DC, eds.). Academic Press, New York, 1991, pp. 61-102.
31. Furman PA, Fyle JA, St. Clair MH, Weinhold K, Rideout JL, Freeman GA, Nusinoff-Lehrman S, Bolognesi DP, Broder S, Mitsuya H, and Barry DW: Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333-8337.
32. Tomevik Y, Jacobson B, Britton S, and Eriksson S: Intracellular metabolism of 3′-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1991; 7:751-759.
33. Balzarini J, Herdewijn P, and De Clercge E: Differential patterns of intracellular metabolism of 2′,3′-dededydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem 1989;264: 6127-6133.
34. Ho H-T and Hitchcock MJM: Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother 1989;33:844-849.
35. Wu JC, Warren TC, Adams J, Proudfoot J, Skiles J, Raghavan P, Perry C, Potocky I, Fairina PR, and Grob PM: A novel dipyridodizepinone inhibitor of HIV-1 reverse transcriptase acts through a non-substrate binding site. Biochemistry 1991;30:2022-2026.
36. Cohen KA, Hopkins J, Ingraham RH, Pargellis C, Grob PM, Wu JC, Palladino DEH, Kinkade P, Warren TC, Robers S, Adams J, and Fairina PR: Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J Biol Chem 1991;226:14670-14674.
37. Schinazi RF, Mead JR, and Feorino PM: Insight into HIV chemotherapy. AIDS Res Hum Retroviruses 1992;8:963-990.
38. Mazzulli T, Rusconi S, Merrill DP, Daquila RT, Moonis M, Chou T-C, and Hirsch MS: Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Agents Chemother 1994;38: 656-661.
39. 4, and recombinant interferon-alpha A. J Infect Dis 1990;161:1059-1067.
40. Popovic M, Sarngadharan MG, Read E, and Gallo RC: Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;224:497-500.
41. Ratner L, Haseltine W, Patarce R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, Ivanoff L, Petteway SR Jr, Pearson ML, Lautenberger JA, Papas TS, Ghrayeb J, Change NT, Gallo RC, and Wong-Staal F: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (London) 1985;313:277-284.
42. Gingeras TR, Prodanovich P, Latimer T, Guatelli JC, Richman DD, and Barringer KJ: Use of self-sustained sequence replication amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus. J Infect Dis 1991;164:1066-1074.
43. Scudiero DA, Shoemaker RH, Paul KD, Monks A, Tieney S, Hafziget TH, Currens JJ, Sheriff D, and Boyd MR: Evaluation of soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-1833.
44. Richman DD, Rosenthal AS, Skoog M, Echner RJ, Chou T-C, Sabo JP, and Merluzzi VJ: B1-RG-589 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 1991;35:305-308.